How does milsaperidone work in the body?
Milsaperidone is a drug in the “prokinetic”/anti-nausea category that acts mainly on the serotonin (5-HT) system and dopamine receptors in the gut. Its therapeutic effects are largely linked to blocking certain serotonin receptor subtypes and relieving serotonin- and dopamine-driven signaling that can impair gastrointestinal motility.
Which receptors does it target (and what does that do)?
Milsaperidone’s mechanism is described in terms of receptor antagonism:
- Serotonin receptors: By blocking specific 5-HT receptors, it helps normalize gut motility and can reduce nausea related to abnormal gastrointestinal sensory signaling.
- Dopamine receptors: By antagonizing dopamine receptors that influence motility, it promotes more effective gastric emptying and intestinal transit.
What results from that receptor activity?
By shifting signaling in the gut away from motility-inhibiting pathways, milsaperidone is used to help with symptoms related to delayed gastric emptying and functional dyspepsia patterns, where improved motility can reduce symptoms like nausea and upper gastrointestinal discomfort.
How does this compare to other GI prokinetics?
Compared with older dopamine antagonists (many of which primarily block dopamine D2 receptors), milsaperidone is characterized by its combined action on serotonin-linked pathways as well as dopamine-related mechanisms, which is part of why it’s positioned as a distinct prokinetic/antiemetic option.
Are there important safety implications tied to the mechanism?
Yes. Because dopamine and serotonin receptor pathways are involved, side effects can overlap with class effects seen in drugs that modulate these systems (for example, effects related to central nervous system signaling and gastrointestinal signaling balance). The exact risk profile depends on dose and patient factors.
Sources: none provided.